Although some studies have linked 22q11.22 deletions, particularly those involving the loss of PRAME, to tumor progression and poor prognosis in hDLBCL and other B-cell malignancies49,50, others argue that this deletion occurs as a consequence of normal IGL rearrangement during B-cell development and is likely not pathogenic51,52. Here, PRAME is linked to neoplasm.